Phase I/II Trial of Gilteritinib (ASP2215) in FLT3-Mutated Relapsed/Refractory AML


Phase I/II Trial of Gilteritinib (ASP2215) in FLT3-Mutated Relapsed/Refractory AML
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Altman JK et al. Antileukemic activity and tolerability of ASP2215 80mg and greater in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia: Results from a Phase 1/2, open-label, dose-escalation/dose-response study. Proc ASH 2015;Abstract 321.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.